Kodiak Sciences Inc. Stock Price, News & Analysis

Kodiak Sciences (Nasdaq: KOD) priced an upsized underwritten public offering of 6,956,522 shares of common stock at $23.00 per share, producing expected gross proceeds of approximately $160 million before underwriting discounts, commissions and expenses.

The offering is expected to close on or about December 18, 2025, subject to customary closing conditions. Kodiak granted underwriters a 30-day option to buy up to an additional 1,043,478 shares at the public offering price less underwriting discounts and commissions. All shares are being sold by Kodiak Sciences.

J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank are joint book-running managers. The shares are offered under a shelf registration on Form S-3 declared effective June 2, 2023, and prospectus materials have been filed with the SEC.

Kodiak Sciences (Nasdaq: KOD) announced a proposed underwritten public offering of 6,000,000 shares of common stock with a 30-day option for underwriters to purchase up to an additional 900,000 shares at the public offering price, less underwriting discounts and commissions. All offered shares will be sold by Kodiak Sciences and the offering is subject to market and other conditions. The shares are being offered pursuant to a shelf registration on Form S-3 declared effective by the SEC on June 2, 2023. J.P. Morgan, Jefferies, Evercore ISI and UBS are joint book-running managers.

Kodiak Sciences (Nasdaq: KOD) reported Q3 2025 results and business highlights on Nov 13, 2025. The company ended Q3 with $72.0 million cash and posted a Q3 net loss of $61.5 million ($1.16 per share). Clinical progress included week-20 APEX data for KSI-101 showing >50% of patients with ≥15-letter BCVA gains and ≥90% retina dryness at top doses, faster-than-expected PEAK/PINNACLE enrollment, and completed enrollment (~690 subjects) in Phase 3 DAYBREAK. Multiple Phase 3 topline dates are on track across 1Q–4Q 2026–2027 and a planned BLA filing is targeted after 2026 readouts.

Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth, M.D. will present at two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30pm GMT (8:30am PST) and the 8th Annual Evercore Healthcare Conference in Coral Gables on Wednesday, December 3, 2025 at 3:00pm EST (12:00pm PST).

The Jefferies appearance will be a presentation; the Evercore session will be a fireside chat. A live webcast of both events will be available in the Events and Presentations section of Kodiak's investor website at http://ir.kodiak.com/ and will be available for replay for a limited time.

Kodiak (Nasdaq: KOD) reported Week 20 follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation (MESI) on Nov 5, 2025. Key results: ≥90% of patients in the top two dose levels (5 mg, 10 mg) achieved and sustained absence of intraretinal and subretinal fluid; mean BCVA gains from baseline to Week 20 were +13.4 letters (5 mg) and +15.4 letters (10 mg); proportions with ≥15-letter gain were 62% (5 mg) and 54% (10 mg). Mean OCT CST reductions were up to -230.1 microns. KSI-101 was described as well tolerated and the top two doses are advancing into the actively enrolling Phase 3 PEAK and PINNACLE studies.

Kodiak Sciences (NASDAQ:KOD) has presented new data from their Phase 1b APEX study of KSI-101, a novel bispecific antibody therapy targeting IL-6 and VEGF for treating macular edema secondary to inflammation (MESI). The data shows significant vision improvements, with over 50% of patients in the top two dose levels (5mg and 10mg) achieving ≥15 letter gains.

Key results include mean vision gains of 8.8 to 12.1 letters across dose levels and substantial retinal thickness reductions of 165-240 microns at Week 12. The therapy demonstrated rapid onset, with the majority of patients achieving retinal dryness by Week 8. A separate cohort of diabetic macular edema patients showed 12.0 letter gains at Week 24.

The company is now advancing Phase 3 PEAK and PINNACLE studies testing the 5mg and 10mg doses, with KSI-101 showing a favorable safety profile across all patient groups.

Kodiak Sciences (Nasdaq: KOD) has announced its participation in two major scientific conferences where it will present Phase 1b APEX study data for KSI-101, its bispecific trap-antibody targeting macular edema secondary to inflammation (MESI).

Dr. Charles Wykoff will present the findings at the 25th EURetina Congress in Paris on September 5, 2025, and at The Retina Society 58th Annual Scientific Meeting in Chicago on September 13, 2025. The presentations will focus on KSI-101's dual mechanism of inhibiting both interleukin-6 and vascular endothelial growth factor. Both presentations will be made available on Kodiak's investor relations website.

Harbour BioMed (HKEX: 02142) reported strong 2025 interim results, with total revenue reaching $101.3 million, up 327% year-over-year, and net profit soaring 51-fold to $73.0 million. The company's cash position strengthened to $320 million, a 92% increase from year-end 2024.

Key developments include the BLA acceptance for batoclimab by NMPA for gMG treatment, strategic collaborations with AstraZeneca ($105M equity investment), Windward Bio for HBM9378, and Otsuka for HBM7020. The company advanced multiple clinical-stage programs including porustobart and HBM1020, while expanding its next-generation portfolio with HBM7004 and HBM7020.

The company launched Élancé Therapeutics for obesity treatment and strengthened its platform potential through Nona Biosciences, establishing multiple global partnerships and introducing the AI-assisted Hu-mAtrIx™ drug discovery engine.

Kodiak Sciences (NASDAQ:KOD), a precommercial retina-focused biotech company, will present its glaucoma pipeline programs at the American Chemical Society Fall 2025 Meeting on August 19, 2025, in Washington, D.C.

The company is developing dual-mechanism therapies using its Antibody Biopolymer Conjugate Drug (ABCD) platform. The treatment combines a NLRP3 inhibitor targeting neuroinflammation with an IOP-lowering agent, delivered via quarterly intravitreal injection. Additionally, Kodiak is advancing its VETi™ program, an AI-enabled wearable headset designed to improve clinical trial testing efficiency and accuracy.